Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading RAPT Therapeutics Inc chart...

About the Company

rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.

CEO

Brian Wong

Exchange

NASDAQ

Website

https://www.rapt.com/

$63M

Total Revenue

137

Employees

$287M

Market Capitalization

-2.83

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RAPT News

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

11d ago, source: Business Insider

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and ...

Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?

11d ago, source: Zacks.com on MSN

Investors are always looking for stocks that are poised to beat at earnings season and RAPT Therapeutics, Inc. RAPT may be one such company. The firm has earnings coming up pretty soon, and events are ...

RAPT Apr 2024 10.000 put

2d ago, source: Yahoo Finance

Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based ...

Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns

8d ago, source:

In a report released on March 7, Thomas Smith from Leerink Partners maintained a Hold rating on RAPT Therapeutics (RAPT – Research ...

RAPT Oct 2024 5.000 call

11d ago, source: Yahoo Finance

Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

13d ago, source:

New York, New York-- (Newsfile Corp. - March 5, 2024) - Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors ...

RAPT Therapeutics GAAP EPS of -$0.80

11d ago, source: Seeking Alpha

Net loss for the fourth quarter of 2023 was $30.9 million, compared to $23.0 million for the fourth quarter of 2022. As of December 31, 2023, the Company had cash and cash equivalents and marketable ...

RAPT Therapeutics: Q4 Earnings Insights

11d ago, source: Benzinga.com

RAPT Therapeutics RAPT reported its Q4 earnings results on Thursday, March 7, 2024 at 08:00 AM. Here's what investors need to know about the announcement. RAPT Therapeutics beat estimated earnings by ...

Earnings Outlook For Relmada Therapeutics

16h ago, source:

Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-0.83. Relmada Therapeutics bulls ...

Sight Sciences, Inc.

1y ago, source: CNN

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye ...

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

on MSN ago, source:

Sarepta Therapeutics ( SRPT 1.48%) could have a serious new competitor on the horizon. According to some fresh clinical data ...

RAPT Therapeutics, Inc.: RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

2mon ago, source: Finanznachrichten

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...